{"id":"https://openalex.org/W2761567953","doi":"https://doi.org/10.1002/phar.2046","title":"Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases","display_name":"Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases","publication_year":2017,"publication_date":"2017-10-13","ids":{"openalex":"https://openalex.org/W2761567953","doi":"https://doi.org/10.1002/phar.2046","mag":"2761567953","pmid":"https://pubmed.ncbi.nlm.nih.gov/29028119"},"language":"en","primary_location":{"id":"doi:10.1002/phar.2046","doi":"https://doi.org/10.1002/phar.2046","is_oa":false,"landing_page_url":"https://doi.org/10.1002/phar.2046","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021605461","display_name":"G\u00e9ric Maura","orcid":"https://orcid.org/0000-0001-6597-5122","observed_orcids":["https://orcid.org/0000-0001-6597-5122"]},"institutions":[{"id":"https://openalex.org/I15057530","display_name":"Universit\u00e9 de Bordeaux","ror":"https://ror.org/057qpr032","country_code":"FR","type":"education","lineage":["https://openalex.org/I15057530"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210106115","display_name":"Bordeaux Population Health","ror":"https://ror.org/00xzzba89","country_code":"FR","type":"facility","lineage":["https://openalex.org/I15057530","https://openalex.org/I154526488","https://openalex.org/I4210106115"]},{"id":"https://openalex.org/I4210131891","display_name":"l'Assurance Maladie","ror":"https://ror.org/03am7sg53","country_code":"FR","type":"other","lineage":["https://openalex.org/I4210131891"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"G\u00e9ric Maura","raw_affiliation_strings":["Bordeaux Population Health Research Center, Team PHARMACOEPIDEMIOLOGY-UMR 1219, University of Bordeaux, INSERM, Bordeaux, France","Department of Studies in Public Health, French National Health Insurance (Assurance Maladie/CNAMTS-TS), Paris Cedex 20, France"],"raw_orcid":"https://orcid.org/0000-0001-6597-5122","affiliations":[{"raw_affiliation_string":"Bordeaux Population Health Research Center, Team PHARMACOEPIDEMIOLOGY-UMR 1219, University of Bordeaux, INSERM, Bordeaux, France","institution_ids":["https://openalex.org/I15057530","https://openalex.org/I154526488","https://openalex.org/I4210106115"]},{"raw_affiliation_string":"Department of Studies in Public Health, French National Health Insurance (Assurance Maladie/CNAMTS-TS), Paris Cedex 20, France","institution_ids":["https://openalex.org/I4210131891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007909493","display_name":"C\u00e9cile Billionnet","orcid":"https://orcid.org/0000-0002-1905-3183","observed_orcids":["https://orcid.org/0000-0002-1905-3183"]},"institutions":[{"id":"https://openalex.org/I4210131891","display_name":"l'Assurance Maladie","ror":"https://ror.org/03am7sg53","country_code":"FR","type":"other","lineage":["https://openalex.org/I4210131891"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"C\u00e9cile Billionnet","raw_affiliation_strings":["Department of Studies in Public Health, French National Health Insurance (Assurance Maladie/CNAMTS-TS), Paris Cedex 20, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Studies in Public Health, French National Health Insurance (Assurance Maladie/CNAMTS-TS), Paris Cedex 20, France","institution_ids":["https://openalex.org/I4210131891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026413767","display_name":"Fran\u00e7ois Alla","orcid":"https://orcid.org/0000-0002-5793-7190","observed_orcids":["https://orcid.org/0000-0002-5793-7190"]},"institutions":[{"id":"https://openalex.org/I4210131891","display_name":"l'Assurance Maladie","ror":"https://ror.org/03am7sg53","country_code":"FR","type":"other","lineage":["https://openalex.org/I4210131891"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Fran\u00e7ois Alla","raw_affiliation_strings":["Department of Studies in Public Health, French National Health Insurance (Assurance Maladie/CNAMTS-TS), Paris Cedex 20, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Studies in Public Health, French National Health Insurance (Assurance Maladie/CNAMTS-TS), Paris Cedex 20, France","institution_ids":["https://openalex.org/I4210131891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059157113","display_name":"Joshua J. Gagne","orcid":"https://orcid.org/0000-0001-5428-9733","observed_orcids":["https://orcid.org/0000-0001-5428-9733"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua J. Gagne","raw_affiliation_strings":["Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":null,"display_name":"Antoine Pariente","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I15057530","display_name":"Universit\u00e9 de Bordeaux","ror":"https://ror.org/057qpr032","country_code":"FR","type":"education","lineage":["https://openalex.org/I15057530"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I3018323443","display_name":"Centre Hospitalier Universitaire de Bordeaux","ror":"https://ror.org/01hq89f96","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018323443"]},{"id":"https://openalex.org/I4210106115","display_name":"Bordeaux Population Health","ror":"https://ror.org/00xzzba89","country_code":"FR","type":"facility","lineage":["https://openalex.org/I15057530","https://openalex.org/I154526488","https://openalex.org/I4210106115"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Antoine Pariente","raw_affiliation_strings":["Bordeaux Population Health Research Center, Team PHARMACOEPIDEMIOLOGY-UMR 1219, University of Bordeaux, INSERM, Bordeaux, France","Pharmacologie, CHU de Bordeaux, Bordeaux, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bordeaux Population Health Research Center, Team PHARMACOEPIDEMIOLOGY-UMR 1219, University of Bordeaux, INSERM, Bordeaux, France","institution_ids":["https://openalex.org/I15057530","https://openalex.org/I154526488","https://openalex.org/I4210106115"]},{"raw_affiliation_string":"Pharmacologie, CHU de Bordeaux, Bordeaux, France","institution_ids":["https://openalex.org/I3018323443"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5021605461"],"corresponding_institution_ids":["https://openalex.org/I15057530","https://openalex.org/I154526488","https://openalex.org/I4210106115","https://openalex.org/I4210131891"],"apc_list":{"value":4030,"currency":"USD","value_usd":4030},"apc_paid":null,"fwci":4.007,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.94869263,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"38","issue":"1","first_page":"6","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.7509999871253967},{"id":"https://openalex.org/keywords/dabigatran","display_name":"dabigatran","score":0.9760000109672546},{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":1.0},{"id":"https://openalex.org/keywords/vitamin-k-antagonists","display_name":"vitamin K antagonists","score":0.9800000190734863},{"id":"https://openalex.org/keywords/non-valvular-atrial-fibrillation","display_name":"non-valvular atrial fibrillation","score":0.9340000152587891},{"id":"https://openalex.org/keywords/oral-anticoagulants","display_name":"oral anticoagulants","score":0.8830000162124634},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.9409999847412109},{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":0.8849999904632568},{"id":"https://openalex.org/keywords/competing-risk-analysis","display_name":"competing risk analysis","score":0.7120000123977661},{"id":"https://openalex.org/keywords/stroke-prevention","display_name":"stroke prevention","score":0.4490000009536743},{"id":"https://openalex.org/keywords/bleeding-risk","display_name":"bleeding risk","score":0.8539999723434448},{"id":"https://openalex.org/keywords/anticoagulant-switching","display_name":"anticoagulant switching","score":0.6970000267028809},{"id":"https://openalex.org/keywords/inverse-probability-of-treatment-weighting","display_name":"inverse probability of treatment weighting","score":0.8220000267028809}],"concepts":[{"id":"https://openalex.org/C2778810321","wikidata":"https://www.wikidata.org/wiki/Q419345","display_name":"Dabigatran","level":4,"score":0.9480262398719788},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.9427422285079956},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8476560711860657},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.754930317401886},{"id":"https://openalex.org/C2776704044","wikidata":"https://www.wikidata.org/wiki/Q2852541","display_name":"Vitamin K antagonist","level":4,"score":0.6980308294296265},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.6804857850074768},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.5420011878013611},{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.5059110522270203},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49650222063064575}],"mesh":[{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069604","descriptor_name":"Dabigatran","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069604","descriptor_name":"Dabigatran","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001281","descriptor_name":"Atrial Fibrillation","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D001281","descriptor_name":"Atrial Fibrillation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005602","descriptor_name":"France","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006470","descriptor_name":"Hemorrhage","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006760","descriptor_name":"Hospitalization","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014812","descriptor_name":"Vitamin K","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016208","descriptor_name":"Databases, Factual","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019934","descriptor_name":"International Normalized Ratio","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020521","descriptor_name":"Stroke","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/phar.2046","doi":"https://doi.org/10.1002/phar.2046","is_oa":false,"landing_page_url":"https://doi.org/10.1002/phar.2046","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},{"id":"pmid:29028119","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29028119","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy","raw_type":"Comparative Study"},{"id":"pmh:oai:HAL:hal-03043528v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-03043528","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, In press, 38 (1), pp.6-18. &#x27E8;10.1002/phar.2046&#x27E9;","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:oskar-bordeaux.fr:20.500.12278/21324","doi":null,"is_oa":false,"landing_page_url":"https://oskar-bordeaux.fr/handle/20.500.12278/21324","pdf_url":null,"source":{"id":"https://openalex.org/S4306402569","display_name":"Oskar-Bordeaux (Universite de Bordeaux)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I15057530","host_organization_name":"Universit\u00e9 de Bordeaux","host_organization_lineage":["https://openalex.org/I15057530"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article de revue"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":49,"referenced_works":["https://openalex.org/W784008945","https://openalex.org/W1547546593","https://openalex.org/W1567051068","https://openalex.org/W1741567663","https://openalex.org/W1843312881","https://openalex.org/W1913182214","https://openalex.org/W1934003446","https://openalex.org/W1974546914","https://openalex.org/W1975757685","https://openalex.org/W1979206887","https://openalex.org/W1982173905","https://openalex.org/W1986049531","https://openalex.org/W2003479746","https://openalex.org/W2016722530","https://openalex.org/W2030404218","https://openalex.org/W2062765161","https://openalex.org/W2063844762","https://openalex.org/W2066380890","https://openalex.org/W2074206824","https://openalex.org/W2074627993","https://openalex.org/W2076544060","https://openalex.org/W2085501100","https://openalex.org/W2097854437","https://openalex.org/W2106143461","https://openalex.org/W2110818436","https://openalex.org/W2110901751","https://openalex.org/W2121690051","https://openalex.org/W2135241452","https://openalex.org/W2136489990","https://openalex.org/W2147018083","https://openalex.org/W2154746519","https://openalex.org/W2164643105","https://openalex.org/W2169793874","https://openalex.org/W2171284718","https://openalex.org/W2178817764","https://openalex.org/W2206494890","https://openalex.org/W2220556496","https://openalex.org/W2240734593","https://openalex.org/W2253985091","https://openalex.org/W2264767503","https://openalex.org/W2295147099","https://openalex.org/W2464204870","https://openalex.org/W2504388219","https://openalex.org/W2515405935","https://openalex.org/W2517582840","https://openalex.org/W2524023308","https://openalex.org/W2607741304","https://openalex.org/W2617556060","https://openalex.org/W3004050106"],"related_works":["https://openalex.org/W4298009183","https://openalex.org/W2464204870","https://openalex.org/W2924906407","https://openalex.org/W3106348194","https://openalex.org/W2981320481","https://openalex.org/W1608468714","https://openalex.org/W2754885744","https://openalex.org/W2802930797","https://openalex.org/W6921156400","https://openalex.org/W2905437677"],"abstract_inverted_index":{"BACKGROUND:":[0],"Direct":[1],"oral":[2,77],"anticoagulants":[3],"(DOACs)":[4],"have":[5],"been":[6],"proposed":[7],"as":[8,73,109,246],"a":[9,46,74,82,110],"more":[10],"convenient":[11],"alternative":[12],"to":[13,51,120,214,221,231,292],"vitamin":[14],"K":[15],"antagonists":[16],"(VKAs),":[17],"which":[18],"are":[19],"commonly":[20],"associated":[21],"with":[22,85,89,263,270,281],"poor":[23],"treatment":[24,144,250],"persistence":[25,269,280],"in":[26,57,197,202],"non-valvular":[27],"atrial":[28],"fibrillation":[29],"(nv-AF).":[30],"METHODS:":[31],"Using":[32],"data":[33],"from":[34,254],"the":[35,53,90],"French":[36],"national":[37],"health":[38],"care":[39],"databases":[40],"(R\u00e9gime":[41],"G\u00e9n\u00e9ral,":[42],"50":[43],"million":[44],"beneficiaries),":[45],"cohort":[47,257],"study":[48,258],"was":[49,71],"conducted":[50],"compare":[52,121],"1-year":[54,115,161],"non-persistence":[55,261,296],"rates":[56,117,163],"nv-AF":[58],"patients":[59,206,289],"initiating":[60],"dabigatran":[61,167,203,224,272],"(N=11,141)":[62],"or":[63,81],"rivaroxaban":[64,183,205,216,274],"(N=11,126)":[65],"versus":[66,124,184],"VKA":[67,105,170,185,282],"(N=11,998).":[68],"Treatment":[69],"discontinuation":[70,116,162],"defined":[72],"switch":[75],"between":[76,114,241],"anticoagulant":[78],"(OAC)":[79],"classes":[80,243],"60-day":[83],"gap":[84,103],"no":[86,94],"medication":[87],"coverage,":[88],"additional":[91],"criterion":[92],"of":[93,143,155,249],"reimbursement":[95],"for":[96,104,166,169,182,285],"international":[97],"normalized":[98],"ratio":[99],"monitoring":[100],"during":[101],"this":[102,255],"patients.":[106],"Considering":[107],"death":[108,245],"competing":[111,247],"risk,":[112],"differences":[113,194],"were":[118,131,138,164,195,235,290],"used":[119],"each":[122],"DOAC":[123,149],"VKA.":[125],"The":[126],"95%":[127],"confidence":[128],"intervals":[129],"(CIs)":[130],"estimated":[132],"via":[133],"bootstrapping.":[134],"Baseline":[135],"patient":[136],"characteristics":[137],"adjusted":[139],"using":[140],"inverse":[141],"probability":[142],"weighting.":[145],"Subgroup":[146],"analyses":[147],"considered":[148],"dose":[150],"at":[151],"initiation,":[152],"age,":[153],"risk":[154],"stroke,":[156],"and":[157,181,204,223,244,266,273],"bleeding.":[158],"RESULTS:":[159],"Adjusted":[160],"higher":[165],"than":[168,279],"new":[171,186,227],"users":[172,187,228],"(36.8%":[173],"vs":[174,189,210,217],"30.2%;":[175],"difference:":[176],"6.6%":[177],"[95%":[178],"CI,":[179],"5.5-7.6])":[180],"(33.4%":[188],"30.4%;":[190],"3.0%":[191],"[1.9-4.1]).":[192],"Similar":[193],"found":[196],"all":[198,264],"subgroup":[199],"analyses,":[200],"except":[201],"<75":[207],"years":[208],"(dabigatran":[209],"VKA:":[211,218],"0.3%":[212],"[-1.4":[213],"1.8];":[215],"-2.6%":[219],"[-4.3":[220],"-0.9])":[222],"150":[225],"mg":[226],"(-1.1%":[229],"[-3.1":[230],"0.7]).":[232],"Consistent":[233],"results":[234],"obtained":[236],"when":[237],"considering":[238],"both":[239,271],"switches":[240],"OAC":[242],"risks":[248],"discontinuation.":[251],"CONCLUSION:":[252],"Results":[253],"nationwide":[256],"showed":[259],"high":[260,295],"levels":[262],"OACs":[265],"suggest":[267],"that":[268],"therapy":[275],"is":[276],"not":[277],"better":[278],"therapy.":[283],"Hospitalizations":[284],"bleeding":[286],"among":[287],"non-persistent":[288],"unlikely":[291],"explain":[293],"these":[294],"rates.":[297]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-10-20T00:00:00"}